Study to Evaluate the Safety and Efficacy of DR-3001 Versus Placebo in Women With Overactive Bladder
Launched by DURAMED RESEARCH · Sep 14, 2005
Trial Information
Current as of July 09, 2025
Completed
Keywords
ClinConnect Summary
This is a multi-center, randomized, placebo-controlled study to compare two doses of DR-3001 to placebo for a 12-week treatment period. The overall duration of patient participation will be for approximately 19 weeks. Patients will be required to keep a daily diary record of study medication use and incontinence episodes
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of overactive bladder and incontinence for at least 6 months
- • Using birth control or menopausal
- • Willing to discontinue current medication for overactive bladder
- Exclusion Criteria:
- • Pregnant or given birth in the last 6 months
- • Three or more urinary tract infections a year
- • Uncontrolled glaucoma, hypertension, diabetes or myasthenia gravis
- • History of bladder cancer, ulcerative colitis or severe constipation
- • Any contraindication to vaginal delivery systems
About Duramed Research
Duramed Research is a leading clinical trial sponsor dedicated to advancing medical innovation through rigorous research and development. With a strong focus on enhancing patient outcomes, Duramed specializes in conducting phase I to phase IV clinical trials across a variety of therapeutic areas. The organization is committed to upholding the highest standards of scientific integrity and regulatory compliance, leveraging a team of experienced professionals and state-of-the-art methodologies. By fostering collaborations with healthcare providers and utilizing patient-centric approaches, Duramed Research aims to contribute significantly to the discovery and development of new therapies that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Diego, California, United States
Decatur, Georgia, United States
Memphis, Tennessee, United States
San Antonio, Texas, United States
Denver, Colorado, United States
Philadelphia, Pennsylvania, United States
Providence, Rhode Island, United States
Salt Lake City, Utah, United States
Huntsville, Alabama, United States
Boise, Idaho, United States
Moorestown, New Jersey, United States
Dallas, Texas, United States
Seattle, Washington, United States
Birmingham, Alabama, United States
Little Rock, Arkansas, United States
Waterbury, Connecticut, United States
Aventura, Florida, United States
Jeffersonville, Indiana, United States
Shreveport, Louisiana, United States
Jackson, Mississippi, United States
Edison, New Jersey, United States
Williamsville, New York, United States
Lancaster, Pennsylvania, United States
Charleston, South Carolina, United States
Milwaukee, Wisconsin, United States
Vancouver, British Columbia, Canada
Toronto, Ontario, Canada
Nashville, Tennessee, United States
Evansville, Indiana, United States
Mobile, Alabama, United States
Phoenix, Arizona, United States
Tucson, Arizona, United States
San Diego, California, United States
Aurora, Colorado, United States
Colorado Springs, Colorado, United States
Gainesville, Florida, United States
Sandy Springs, Georgia, United States
Fort Wayne, Indiana, United States
Indianapolis, Indiana, United States
Meridian, Indiana, United States
Lebanon, New Hampshire, United States
Livingston, New Jersey, United States
Portland, Oregon, United States
Houston, Texas, United States
Waco, Texas, United States
Tacoma, Washington, United States
Patients applied
Trial Officials
Medical Monitor
Principal Investigator
Duramed Research
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials